Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type of blood cancer. The studies were led by Adam Kittai, MD, Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai and the Director of Mount Sinai’s CLL Program. As one of the world’s leading experts on Richter transformation, Dr. Kittai aims to increase awareness about Mount Sinai’s CLL program and welcome patients in need of a second opinion.
This article was originally published on MedicalXpress.com
